FBT:NYE-First Trust NYSE Arca Biotechnology Index Fund (USD)

ETF | Health |

Last Closing

USD 160.84

Change

-3.55 (-2.16)%

Market Cap

N/A

Volume

0.02M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-21 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-3.12 (-2.32%)

USD 35.08B
FHLC Fidelity® MSCI Health Care In..

-1.56 (-2.45%)

USD 2.50B
FXH First Trust Health Care AlphaD..

-2.83 (-2.73%)

USD 0.90B
XHE SPDR® S&P Health Care Equipme..

-2.55 (-3.06%)

USD 0.16B
IDNA iShares Genomics Immunology an..

-0.39 (-1.91%)

USD 0.10B
XHS SPDR® S&P Health Care Service..

-2.77 (-2.75%)

USD 0.09B
SBIO ALPS Medical Breakthroughs ETF

-0.78 (-2.66%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.83 (-3.00%)

USD 0.04B
BBP Virtus LifeSci Biotech Product..

-1.43 (-2.50%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.64 (-3.42%)

USD 0.01B

ETFs Containing FBT

FHM:CA 0.00 % 0.78 %

N/A

N/A
FBT:CA First Trust NYSE Arca Bio.. 0.00 % 0.00 %

-0.66 (-2.30%)

CAD 1.83M

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.23% 71% C- 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.23% 71% C- 36% F
Trailing 12 Months  
Capital Gain 3.89% 90% A- 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.89% 90% A- 49% F
Trailing 5 Years  
Capital Gain -2.49% 38% F 32% F
Dividend Return 1.34% 37% F 3% F
Total Return -1.14% 38% F 18% F
Average Annual (5 Year Horizon)  
Capital Gain 0.81% 38% F 40% F
Dividend Return 1.14% 38% F 30% F
Total Return 0.33% 42% F 9% A-
Risk Return Profile  
Volatility (Standard Deviation) 11.49% 81% B- 74% C
Risk Adjusted Return 9.95% 48% F 30% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.